While Kronos Bio, Inc. is discovering and developing transcription factor-targeting cancer therapies in house, CEO Norbert Bischofberger has turned to his former home to accelerate Kronos’ business strategy by acquiring a pair of abandoned Phase II SYK inhibitors.
Privately held Kronos revealed on 16 July that it is acquiring the mid-stage compounds entospletinib and lanraplenib, which were halted...








